As­traZeneca, Mer­ck score a block­buster ad­vance as Lyn­parza comes through in front­line ovar­i­an can­cer

As­traZeneca’s on­col­o­gy R&D team has suc­cess­ful­ly hit an­oth­er land­mark mile­stone.

The phar­ma gi­ant along with its part­ners at Mer­ck are drum­ming up new, block­buster-sized mar­ket ex­pec­ta­tions for its PARP in­hibitor Lyn­parza as a first-line main­te­nance treat­ment in ovar­i­an can­cer with a quick, top-lev­el an­nounce­ment of their late-stage suc­cess to­day.

In a Phase III tri­al dubbed SO­LO-1, Lyn­parza “sig­nif­i­cant­ly” de­layed dis­ease pro­gres­sion in women with BR­CA-mu­tat­ed ad­vanced ovar­i­an can­cer — the pri­ma­ry end­point. There’s no word on the da­ta just yet, which will be care­ful­ly stud­ied as an­a­lysts as­sess mar­ket im­pact. In­ves­ti­ga­tors gen­er­al­ly hold on to the de­tails for an up­com­ing con­fer­ence — in this case quite pos­si­bly ES­MO in Oc­to­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER